|
1
|
Kazandjian D: Multiple myeloma
epidemiology and survival: A unique malignancy. Semin Oncol.
43:676–681. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Röllig C, Knop S and Bornhäuser M:
Multiple myeloma. Lancet. 385:2197–2208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rajkumar SV and Kumar S: Multiple myeloma:
Diagnosis and treatment. Mayo Clin Proc. 91:101–119. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Attal M, Lauwers-Cances V, Hulin C, Leleu
X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L,
et al: Lenalidomide, bortezomib, and dexamethasone with
transplantation for myeloma. N Engl J Med. 376:1311–1320. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moreau P, Attal M, Hulin C, Arnulf B,
Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D,
et al: Bortezomib, thalidomide, and dexamethasone with or without
daratumumab before and after autologous stem-cell transplantation
for newly diagnosed multiple myeloma (Cassiopeia): A randomised,
open-label, phase 3 study. Lancet. 394:29–38. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rajkumar SV, Dimopoulos MA, Palumbo A,
Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E,
Richardson P, et al: International myeloma working group updated
criteria for the diagnosis of multiple myeloma. Lancet Oncol.
15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moreau P, San Miguel J, Sonneveld P,
Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA,
Ludwig H, Einsele H, et al: Multiple myeloma: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 28 (Suppl 4):iv52–iv61. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rodriguez-Otero P, Paiva B and San-Miguel
JF: Roadmap to cure multiple myeloma. Cancer Treat Rev.
100:1022842021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
San Miguel JF and García-Sanz R:
Prognostic features of multiple myeloma. Best Pract Res Clin
Haematol. 18:569–583. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sathick IJ, Drosou ME and Leung N: Myeloma
light chain cast nephropathy, a review. J Nephrol. 32:189–198.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ludwig H, Drach J, Graf H, Lang A and
Meran JG: Reversal of acute renal failure by bortezomib-based
chemotherapy in patients with multiple myeloma. Haematologica.
92:1411–1414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duncan L, Heathcote J, Djurdjev O and
Levin A: Screening for renal disease using serum creatinine: Who
are we missing? Nephrol Dial Transplant. 16:1042–1046. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baxmann AC, Ahmed MS, Marques NC, Menon
VB, Pereira AB, Kirsztajn GM and Heilberg IP: Influence of muscle
mass and physical activity on serum and urinary creatinine and
serum cystatin C. Clin J Am Soc Nephrol. 3:348–354. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prigent A: Monitoring renal function and
limitations of renal function tests. Semin Nucl Med. 38:32–46.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stevens PE and Levin A; Kidney Disease, :
Improving Global Outcomes Chronic Kidney Disease Guideline
Development Work Group Members: Evaluation and management of
chronic kidney disease: Synopsis of the kidney disease: Improving
global outcomes 2012 clinical practice guideline. Ann Intern Med.
158:825–830. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim SW, Jung HW, Kim CH, Kim KI, Chin HJ
and Lee H: A new equation to estimate muscle mass from creatinine
and cystatin C. PLoS One. 11:e01484952016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He L, Li J, Zhan J, Yi F, Fan X, Wei Y and
Zhang W: The value of serum cystatin C in early evaluation of renal
insufficiency in patients undergoing chemotherapy: A systematic
review and meta-analysis. Cancer Chemother Pharmacol. 83:561–571.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kashani KB, Frazee EN, Kukrálová L,
Sarvottam K, Herasevich V, Young PM, Kashyap R and Lieske JC:
Evaluating muscle mass by using markers of kidney function:
Development of the sarcopenia index. Crit Care Med. 45:e23–e29.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang T, Zhuo Y, Xie L, Wang H and Yang M:
Sarcopenia index based on serum creatinine and cystatin C is
associated with 3-year mortality in hospitalized older patients.
Sci Rep. 10:12602020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng C, Wang E, Li JS, Xie K, Luo C, Ge
QY, Hu LW and Shen Y: Serum creatinine/cystatin C ratio as a
screening tool for sarcopenia and prognostic indicator for patients
with esophageal cancer. BMC Geriatr. 22:2072022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rule AD, Bailey KR and Turner ST: What is
the goal with endogenous filtration markers-estimation of GFR or
prediction of kidney outcomes? Am J Kidney Dis. 58:865–867. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Patel SS, Molnar MZ, Tayek JA, Ix JH,
Noori N, Benner D, Heymsfield S, Kopple JD, Kovesdy CP and
Kalantar-Zadeh K: Serum creatinine as a marker of muscle mass in
chronic kidney disease: Results of a cross-sectional study and
review of literature. J Cachexia Sarcopenia Muscle. 4:19–29. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bukabau JB, Sumaili EK, Cavalier E, Pottel
H, Kifakiou B, Nkodila A, Makulo JRR, Mokoli VM, Zinga CV, Longo
AL, et al: Performance of glomerular filtration rate estimation
equations in Congolese healthy adults: The inopportunity of the
ethnic correction. PLoS One. 13:e01933842018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mulaomerović A, Halilbasić A, Cickusić E,
Zavasnik-Bergant T, Begić L and Kos J: Cystatin C as a potential
marker for relapse in patients with non-Hodgkin B-cell lymphoma.
Cancer Lett. 248:192–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kos J, Krasovec M, Cimerman N, Nielsen HJ,
Christensen IJ and Brünner N: Cysteine proteinase inhibitors stefin
A, stefin B, and cystatin C in sera from patients with colorectal
cancer: Relation to prognosis. Clin Cancer Res. 6:505–511.
2000.PubMed/NCBI
|
|
26
|
Zhang J, Jiang Y, Guo D, Liu HY, Hong L,
Qi J and Huang H: The role of cystatin C in multiple myeloma. Int J
Lab Hematol. 44:135–141. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nückel H, Langer C, Herget-Rosenthal S,
Wichert M, Assert R, Döhner H, Dührsen U and Liebisch P: Prognostic
significance of serum cystatin C in multiple myeloma. Int J
Hematol. 95:545–550. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Terpos E, Katodritou E, Tsiftsakis E,
Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E,
Anargyrou K, Tsionos K, et al: Cystatin-C is an independent
prognostic factor for survival in multiple myeloma and is reduced
by bortezomib administration. Haematologica. 94:372–379. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jung CY, Kim HW, Han SH, Yoo TH, Kang SW
and Park JT: Creatinine-cystatin C ratio and mortality in cancer
patients: A retrospective cohort study. J Cachexia Sarcopenia
Muscle. 13:2064–2072. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen Z, Zha L, Ma X, Xu J, Huang D, Wu W,
Chen L, Yang F, Liao W and Wang W: Serum creatinine/cystatin C
ratio as a predictor of in-hospital mortality in patients
hospitalized with acute exacerbation of chronic obstructive
pulmonary disease. Lung. 200:609–617. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao S, Xie H, Wei L, Liu M, Liang Y, Wang
Q, Tang S and Gan J: Serum creatinine/cystatin C ratio as a
prognostic indicator for patients with colorectal cancer. Front
Oncol. 13:11555202023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kwon WS, Kim TS, Nahm CH, Moon Y and Kim
JJ: Aberrant cystatin-C expression in blood from patients with
breast cancer is a suitable marker for monitoring tumor burden.
Oncol Lett. 16:5583–5590. 2018.PubMed/NCBI
|
